TA868 · HST
Recommended within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy, contingent on commercial arrangement (simple discount patient access scheme)
Source documents
Intervention
Condition
Comparators
| Name | Type | Established | Committee preferred |
|---|---|---|---|
| patisiran | active drug | Yes | — |
Economic model
Methodological decisions (2)
Number of vials of patisiran used per person: company used pharmacy data showing vials used, but clinical experts suggested more vials would be used in clinical practice than in the clinical trial
Company: Estimated costs for patisiran using pharmacy data on vials used per person
Committee: Used pharmacy data showing higher vial usage; acknowledged clinical trial scenario where more vials used would make vutrisiran more cost saving
ICER impact: decreases
Administration time and costs for patisiran: the cost savings for vutrisiran depend on administration time and type of healthcare professional administering patisiran
Company: Estimated administration costs for patisiran
Committee: Clinical experts agreed with company's estimate of administration time; higher administration costs for patisiran increase vutrisiran's cost savings
ICER impact: decreases
Commercial arrangement
Special considerations
Cross-references